Loading page
Loading page
Loading substance route
Redosing may result in dangerous cumulative effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Early reports suggest 3-HO-PCP is likely to be moderately addictive with notable habit-forming properties. It appears to be more habit-forming than dissociatives such as MXE, ketamine, and DCK. Compulsive redosing is reported, particularly prominent when smoked or vaporized due to the abrupt onset and offset of effects.
When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops usage. The severity and nature of withdrawal symptoms are not well documented.
The exact toxic and lethal dosage is unknown. 3-HO-PCP has an extremely brief history of human usage and its toxicity has not been studied in any scientific context.
Repeated and excessive use over extended periods is likely to cause bladder and urinary tract problems similar to those seen with ketamine, though potentially to a lesser extent because 3-HO-PCP's higher potency means less material needs to be consumed.
Acute cardiovascular effects including abnormal heartbeat, increased blood pressure, and increased heart rate occur during intoxication.
Respiratory depression may occur, particularly at higher doses or when combined with other depressants.
Reports suggest this compound may produce more physical side effects such as muscle soreness and flu-like symptoms during or shortly after administration, which may indicate it is uniquely more dangerous or toxic than related dissociatives at higher doses.
There is a notable risk of psychosis, delusions, and mania, particularly with chronic use, high doses, or compulsive redosing before fully sober. As an analogue of PCP, which reportedly causes higher rates of mania and psychosis than other dissociatives, similar concerns apply. Avoiding consecutive daily use and staying within recommended dosage ranges is advised to reduce this risk.
Seizures can likely occur in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued, or undernourished. The extent to which this effect can be produced is not well established.
3-HO-PCP was first synthesized in 1978 during investigations into the structure-activity relationships of phencyclidine (PCP) derivatives. Throughout the 1980s, researchers continued to characterize its pharmacological properties, discovering its activity at opioid receptors in animal models during…
Controlled under Nařízení vlády č. 463/2013 Sb. (§ 1, d), 1.). Permitted for research purposes and restricted therapeutic applications only.
Prohibited substance under Swedish drug control legislation.
Classified as a controlled drug under Turkish law. Possession, production, supply, and importation are prohibited.
Not listed as a controlled substance under the Betäubungsmittelgesetz (BtMG). However, under §2 of the Arzneimittelgesetz (AMG), sale for human consumption remains prohibited.
Specifically named as a controlled substance in Verzeichnis E of Swiss narcotics legislation.
Controlled under the Misuse of Drugs Act 1971 via the arylcyclohexylamine generic clause introduced by S.I. 2013/239, effective February 26, 2013. As a derivative of 1-phenylcyclohexylamine with a 1-piperidyl group and hydroxy substitution on the phenyl ring, it falls within this catch-all provision. Possession, production, supply, and importation are criminal offenses.
16 sources cited
